Sanderink, W. B. G.
Strobbe, L. J. A.
Bult, P.
Schlooz-Vries, M. S.
Lardenoije, S.
Venderink, D. J.
Sechopoulos, I.
Karssemeijer, N.
Vreuls, W.
Mann, R. M. http://orcid.org/0000-0001-8111-1930
Funding for this research was provided by:
KWF Kankerbestrijding (KUN 2015-8086)
Medtronic
Article History
Received: 5 June 2020
Accepted: 15 July 2020
First Online: 1 August 2020
Compliance with ethical standards
:
: The authors of this manuscript declare relationships with the following companies, whose products or services may be related to the subject matter of the article. In an associated clinical study, Medtronic the producer of the BLES needles has provided a research grant and non-financial support (BLES device and needles). W.B.G. Sanderink, L.J.A. Strobbe, P. Bult, M.S. Schlooz-Vries, S. Lardenoije, D. Venderink, and W. Vreuls declare no conflicts of interest. I. Sechopoulos has received research grants and research support from Siemens Healthineers, Canon Medical Systems and is scientific advisor of Fischer Medical. N. Karssemeijer is shareholder of Matakina Technology Limited Consultant, QView Medical, ScreenPoint Medical BV and is director of ScreenPoint Medical. R.M. Mann has received research grants and research support from Siemens Healthineers, Bayer Medical, Seno Medical, Elswood, Identification Solutions, Micrima and is Scientific advisor of Screenpoint Medical, Transonic Imaging.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.